Memory versus effector immune responses in oncolytic virotherapies

Cicely Krystyna Macnamara, Raluca Eftimie

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)


The main priority when designing cancer immuno-therapies has been to
seek viable biological mechanisms that lead to permanent cancer eradication
or cancer control. Understanding the delicate balance between the role
of effector and memory cells on eliminating cancer cells remains an elusive
problem in immunology. Here we make an initial investigation into this
problem with the help of a mathematical model for oncolytic virotherapy;
although the model can in fact be made general enough to be applied also to
other immunological problems. Our results show that long-term cancer control
is associated with a large number of persistent effector cells (irrespective
of the initial peak in effector cell numbers). However, this large number of
persistent effector cells is sustained by a relatively large number of memory
cells. Moreover, we show that cancer control from a dormant state cannot
be predicted by the size of the memory population.
Original languageEnglish
Pages (from-to)1-9
JournalJournal of Theoretical Biology
Early online date13 Apr 2015
Publication statusPublished - 21 Jul 2015


  • Cancer modelling
  • Effector and memory cells
  • Tumour control
  • Cancer dormancy


Dive into the research topics of 'Memory versus effector immune responses in oncolytic virotherapies'. Together they form a unique fingerprint.

Cite this